Sectors

KTTA
Pasithea Therapeutics Corp.
0.47
1 x 0.47
8 x 0.49
bid
ask
+
0.01
2.77%
09:43 AM
timesize
Ytd-63.77%
1y-35.08%
0.46
day range
0.49
0.28
52 week range
2.06
Open0.46Prev Close0.45Low0.46High0.49Mkt Cap3.38M
Vol87.26KAvg Vol805.22KEPS-1.60P/E-0.28Forward P/E-3.75
Beta0.29Short Ratio0.32Inst. Own2.87%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1650-d Avg0.60200-d Avg0.781yr Est2.00
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-132024-090-2.87N/AN/A
2024-08-132024-060-3.71N/AN/A
2024-05-142024-030-3.7N/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
Profile
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Insider Holder
DateNameRelationQuantityDescription
2024-06-12NOVAK ALFRED JDirector3.50KStock Award(Grant)
2023-06-01STEINMAN LAWRENCEDirector1.33MPurchase
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29UBS Group AG6.57K17.47K0.52%
2024-09-29Morgan Stanley1.50K3.99K0.12%
2024-09-29Tower Research Capital LLC (TRC)601.001.60K0.05%
2024-09-29Royal Bank of Canada250.00665.000.02%
2024-09-29JP Morgan Chase & Company150.00399.000.01%
2024-09-29Bank of America Corporation18.0047.000.00%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-10-30Fidelity Extended Market Index Fund2.96K7.88K0.23%
2024-10-30Fidelity Series Total Market Index Fund960.002.55K0.08%
Split
SplitDate
1 : 202024-01-02